Category: Health

Doximity on the New York stock exchange for the first public offer on June 24, 2021.

Source: NYSE

Doximity Immerse yourself in artificial intelligence and announces the takeover of Startup Pathway Medical for 63 million US dollars on Thursday.

Pathway has created a AI-driven clinical reference instrument with which doctors can ask questions about guidelines, medication and studies. Pathway's answers are synthesized from medical literature, and Doximity said that the startup based in Montreal has one of the largest structured data records in medicine.

The platform of doximity, which has been referred to for doctors for years, helps the clinicians to stay up to date in medical news, find paperwork, find transfers and to carry out telEAALT appointments with patients. By acquiring paths, Doximity hopes that doctors will also contact the platform to answer their clinical questions.

“We hunted up and low, and I think we found the best company in the room to answer the questions of doctors with AI, and it was not in Silicon Valley,” said Jeff Tangney, co -founder and CEO of doximity, to CNBC in an interview.

The deal ended at the end of July due to a cash view of 26 million US dollars and up to 37 million US dollars in additional equity grants, said Doximity.

According to Tangney, the integration of doximity is in full swing, and companies are testing a combined product with thousands of doctors.

In the meantime, patients regularly turn to AI tools and chatbots to get answers to health-related questions.

While a live stream on Thursday, in which Openai announced his new model GPT-5, CEO Sam Altman said that health questions were one of the largest categories of chatt use, a contribution to X and added that the new model in this area was “much better”.

Doximity already has a free AI product, doximity GPT, with which doctors can generate insurance letters and summarize patient diagrams and reports. Pathway will bring additional “robustness” to the data that Doximity has in the back, said Dr. Amit Phull, Chief Clinical Experience Officer from Doximity.

“What Pathway brings this party or this marriage is that you have a very, very robust back-end data set that connects doses of guidelines for literature to quotes,” Phull told CNBC in an interview.

The Pathway model achieved 96% in the US Medical Licining Examination Benchmark, said Doximity, which doctors have to prove that they can understand and use medical knowledge.

In doximity, which went to the stock exchange in 2021, 10% rose by 10% this year after it rose by 90% in 2024. The company has a market capitalization of around 11 billion US dollars.

The stocks of doximity rose by about 6% on Thursday, after the company had reported results in the first quarter, the estimates exceeded the estimates. Sales rose by 15% to $ 145.9 million compared to the previous year, while analysts expected sales of USD 139.5 million according to LSEG. The result per share of 36 cents exceeded the 30-cent average estimation.

The Omada Health Logo is displayed on a smartphone screen.

SOPA images | Light rocket | Getty pictures

Omada Health Reported quarterly results for the first time since its first public offer in June.

For example, the company worked on the average analyst estimates on the basis of the LSEG:

• Loss per share: 24 cents
• Revenue: 61 million US dollars expected compared to $ 55.2 million

The turnover of the virtual nursing company rose by $ 41.21 million in the second quarter of 49%in the previous year. The company reported a net loss of $ 5.31 million or a loss of 24 cents per share compared to a net loss of $ 10.69 million or a loss of USD 1.40 per share in the same period of the previous year.

“It is a strategically consistent quarter for Omada that takes place at an accelerated pace, which is nice,” said Sean Duffy, CEO of Omada, in an interview with CNBC. “At the highest level there is currently only a large headlight for metabolic supply.”

For all of his year, Omada expects sales between 235 and 241 million US dollars, while analysts expected 222 million US dollars. The company expects to report an adjusted result before interest, depreciation, depreciation and amortization or EBITDA, a loss of $ 9 million to $ 5 million for the entire year, while the analysts, which were expected from facts with a greater loss of $ 20.2 million.

Omada, founded in 2011, offers virtual care programs to support patients with chronic illnesses such as prediabetes, diabetes and high blood pressure. The company describes its approach as a “a visitor that is considered a visit between the visit”, which is supplemented as a broader health ecosystem.

The share opened in June in its debut at Nasdaq at $ 23. At Market Close on Thursday, the shares closed $ 19.46.

Omada said it ended its second quarter with 752,000 members who rose by 52% compared to the previous year.

“The starting weapon of our next chapter has just clicked and we are running hard,” said Duffy. “It was a lot of fun.”

Do not miss these findings from CNBC Pro

Correction: This article has been updated to determine that Omada Health was founded in 2011. The year was incorrectly stated in an earlier version.

Eli Lilly On Thursday he increased his guidance of 2025 and achieved the profit in the second quarter, which exceeded the estimates of the strong demand for weight loss and diabetes from blockbusters and diabetes.

The company increased its sales instructions for 2025 in the amount of 60 to 62 billion US dollars from an earlier outlook of 58 billion US dollars to $ 61 billion for the underlying strength in his business. The pharmaceutical giant also expects its adjusted result of 2025 between 21.75 and 23 $ 23 from an earlier guide of $ 20.78 and USD 22.28 per share.

Eli Lilly said

Also on Thursday, Eli Lilly Lang-expected test data in the late stage released his experimental obesity pill, Orforlipron, the highest dose that patients were able to lose more than 12% of their body weight. This was reached under the expectations of Wall Street and on Thursday the trade at 12% in the Premarket trading by up to 12%.

“I feel good at the value of the company. Investors have to decide what they think,” said Eli Lilly, David Ricks, to CNBCS “Squawk Box”. “But Lilly rolls and you look at the beat and increase, strong growth in the back half. We are happy about the future of our company and for patients who need our products.”

The Diabetes Treatment of the Mounjaro company exceeded expectations for the first quarter and achieved sales of almost 5.2 billion dollars. This increased by 68% compared to the same period last year.

Eli Lilly's weight loss medication Zepbound also defeated estimates and booked sales of $ 3.38 billion for the quarter and increased by 172% compared to the same period last year.

The analysts had expected that Mounjaro and Zepbound would, according to StreetCcount estimates, would achieve 4.49 billion US dollars or 3.06 billion US dollars for sales shots.

“Tirepatide, which is Mounjaro and Zepbound, will probably become the best -selling drug in the industry in his third year,” Ricks told CNBC. “And we have a lot more in the pipeline.”

The following reported Eli Lilly in the second quarter compared to what Wall Street had expected, based on a survey of LSEG analysts:

• Win each share: 6.31 USD expected compared to USD 5.57
• Revenue: $ 15.56 billion expected compared to $ 14.71 billion

The company generated sales of $ 15.56 billion in the second quarter, which increased an increase of 38% compared to the same period in the previous year.

Sales in the United States rose by 38% to 10.81 billion US dollars. Eli Lilly said that this was driven by a 46% increase in volume – or the number of recipes or units sold – for its products, mainly for Mounjaro and Zepbound. This was partially compensated for by lower realized prices of the medication, the company said.

The pharmaceutical giant booked a net profit of 5.66 billion US dollars or $ 6.29 per share for the second quarter. This is compared to a net result of 2.97 billion US dollars or a previous year of USD 3.28 per share.

Without unique elements associated with the value of intangible assets and other adjustments, Eli Lilly made a profit of $ 6.31 per share in the second quarter.

The results also come as Eli Lilly and other drug manufacturers for taxes for pharmaceuticals that were imported into the USA, and confronted his calls to reduce drug prices in the country.

Last week, the President sent letters to Eli Lilly and other companies in which they were able to reduce measures by September 29. The step came after Trump signed an executive regulation in May that repeated a controversial plan, the “most preferred nation” policy, which is supposed to reduce the cost of the drug by connecting the prices of some medicines in the United States abroad.

A combination image shows an injection poison from Zepbound, Eli Lilly's weight loss drug and car from Wegovy, which were made by Novo Nordisk.

Hollie Adams | Reuters

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

In exceptional cases, the Trump administration may give some drug manufacturers a reason to celebrate.

The administration of Trump plans to experiment with the coverage of costly weight loss as part of Medicare and Medicaid, reported Washington Post on Friday. This plan could expand access to millions of Americans with obesity that cannot currently afford Novo Nordisk's Wegovy and Eli LillyBlockbuster GLP-1 medication that costs around $ 1,000 per month before insurance.

In an explanation of CNBC on the plan, the Department of Health and Human Services said that all drug covers are subjected to a “cost-benefit check”. The centers for Medicare and Medicaid services “Do not comment on potential models or reporting,” added the department.

The registered plan – if it ultimately comes into force – would be a great victory for Eli Lilly, Novo Nordisk and many Americans.

Plained insurance coverage for obesity drugs is still the greatest obstacle to access for patients – and it will be a broader recording and sales growth for the two pharmaceutical giants first tours. Many health plans, including Medicare, cover GLP-1 for the treatment of diabetes, but not to obesity. Medicaid medication is limited and varies according to the KFF organization for health policy.

However, it is important to remember that this plan is not exactly new.

In November, the bidges proposed that Medicare and Medicaid cover obesity treatments that would have extended access to around 3.4 million Medicare -privileged and around 4 million Medicaid recipients. The proposal was controversial at the time because it would cost the taxpayer up to 35 billion US dollars in the next decade, showed an analysis of the congress.

The Trump administration dropped this proposal in April, but said that it could rethink the reporting on these medication in the future.

Let us look in the plans registered by the latest reported iteration.

According to the reported pilot plan of the Trump government, state medical programs and Medicare part D plans could voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for “weight management”. This applies to several centers for Medicare and Medicaid services received by the post office.

The plan is expected to begin MedicAid for Medicare plans in April 2026 and January 2027, the post reported.

It is unclear how exactly the plan will play, said Jared Holz, Mazuho Health Care Equity Strategist, in a reference to customers on Friday. Holz said that he expects the government to use some cover parameters in connection with factors such as age, body weight, body mass index and other comorbidities or simultaneous chronic health states.

He also said that the pricing of the drugs would be a “big consideration”. Holz said he expects the government to pay less than the current list prices for drugs. But have that The cover would expand access and could help promote higher sales volumes, as he stated.

Another factor to be taken into account is how much the government is willing to hold up against so-called compound pharmacies, which in rare cases may sell cheaper, non-approved versions of GLP-1S. The pharmaceutical industry is violently opposed to the GLP-1S, since their security and effectiveness of regulatory authorities are not checked and in some cases are illegally sold on a scale.

Holz said that the symptoms of the industry to the government about composed GLP-1S have so far “not been given widespread shutdown”.

Overall, Holz said that the reported willingness of the Trump government to consider the cover of obesity medication was “a little positive for the mood of the industry”.

It is definitely a touch of fresh air for Eli Lilly, Novo Nordisk and other drug makers – including AmgenPresent RochePresent Astrazeneca And Pfizer – they hope to bring their own obesity medication onto the market.

The last six months have been anything but smooth for the broader industry: The Trump administration has included the demands for drug manufacturers to reduce the US drug prices, outdated federal health agencies and could import into the country every day into the country that was imported into the country.

We will continue to see whether this plan will be implemented. So stay up to date on our reporting!

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

The latest in healthcare: the winning season prompted Medicare Advantage player who changed places

Unitedhealth Group Inc. Signpiece on the bottom of the New York Stock Exchange on April 21, 2025.

Michael Nagle | Bloomberg | Getty pictures

After he was reported on the second income rate and the instructions, Unitedhealth Group Finally, his executive sweep by replacing CFO John Rex. Managers about the winnings admitted to a misunderstanding in Medicare Advantage and promised to return to profitability and regain the investor trust.

It was almost two years ago CVS health After printing, the company of low Medicare Advantage Star.

This week CVS beat and increased its prospects for the strength of his MA program. CEO David Joyner, now a year after the start of the job, told me that he feels good when he turned into Aetna and his medical business. In addition, the company achieved market share profits in its shops, which partly thanked Rite Aid customers.

Humana has recorded progress in his turn in a similar way, but CFO Celeste Mellet told me that all insurers deal with price plans for next year in the middle of high medical costs. A big cost driver at the moment, Mellet told CNBC, are oncological medication because some expensive therapies are now used in combination.

The next moment of truth for the Medicare Advantage players will come in the next six weeks – if you learn the fate of your star reviews for 2026 plans.

Read more from CNBCS Bertha Coombs here.

Latest in the healthcare system Tech: Dr. Marc Harrison changes to a strategic advisory role at General Catalyst

Dr. Marc Harrison in the healthcare sector as CEO of General Catalyst's Health Assurance Transformation Company (CEO of General Catalyst “(CEO of General Catalyst” (CEO “has changed, CNBC confirmed.

The risk capital company brought in Harrison and announced the foundation of Hatco in 2023. In a release published at that time, General Catalyst said that the company would work closely with partners of the health system and finally acquire and operate their own health system.

Months later, Hatco announced his plans for the purchase of Summa Health, a non -profit integrated health system in the northeast of Ohio. As part of his new structure, Summa would become a non -profit organization, and General Catalyst said that she would introduce new technically capable solutions that aim to make the supply more accessible and affordable.

The purchase of a health system is an unprecedented step in the risko mobile industry, and the deal was not well received by some members of the Ohio community. Hundreds signed a petition in which the sum asked to remain a non -profit organization and to stop negotiations with Hatco.

The Attorney General of Ohio, Dave Yost, approved the deal in June, although he outlined a number of “enforceable obligations” as part of the agreement. Hatco must inform the Attorney General about transactions, which could trigger antitrust concerns 10 years after the deal.

Harrison visited the Medical Faculty at the end of the 1980s and spent most of his career in health systems, most recently as CEO of Intermountain Healthcare. General Catalyst announced CNBC that Harrison would continue to provide the company's CEO, Hemant Taaneja, clinical knowledge and remains connected to his ecosystem in his new role.

“For Marc and us, it became increasingly clear that Marc's role as a strategic advisor of Hemant Taneja would best be fulfilled while we bring this ambition and this vision to life,” said a general spokesman for catalyst.

Daryl Tol, head of the Health Assurance Ecosystem of General Catalyst, was promoted to Hatco President, said the spokesman. He will lead the company's daily work with Summa Health Leadership.

General Catalyst has also appointed Kate Walsh, the former secretary for health and human services from Massachusetts, the Hatco board. In addition, she will act as chairman of the board at Summa Health as soon as the transaction closes.

“We are grateful for the leadership and collaboration of Marc as a co -founder and CEO to get to the development of HATCO to this point, and we look forward to using his invaluable perspective while we continue to progress,” said the spokesman.

Read more about the reporting of CNBC about Hatco's acquisition of Summa Health.
Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.

The HERS app arranged on a smartphone in New York on February 12, 2025.

Gabby Jones | Bloomberg | Getty pictures

Shares of Hims & Hers Health On Monday, 9% fell back in the extended trade after the Telemealth Company had reported results in the second quarter that missed Wall Street sales expectations.

For example, the company worked on the average analyst estimates on the basis of the LSEG:

• Win each share: 17 cents are expected compared to 15 cents
• Revenue: $ 544.8 million expected compared to USD 552 million

After a press release, sales at HIMS & BE increased in the second quarter of US $ 315.6 million by 73%in the same period of the previous year. In the same period, HIMS & HER reported a net result of $ 42.5 million or 17 cents per share compared to $ 13.3 million or 6 cents per share.

For his third quarter, HIMS & HERS said that it would spend sales between $ 570 million and $ 590 million, while analysts expected $ 583 million. The company stated that its adjusted profit before interest, taxes, depreciation and amortization or EBITDA will be between $ 60 million and $ 70 million for the quarter. 77.1 million US dollars expected from Street Account.

Hims & Her has been controversial in the past few months due to the continued sale of composite GLP-1, which are cheaper versions of the blockbuster diabetes and weight loss medication. MONICATIONS MASS Production in brand treatments can be produced, but the US Food and Drug Administration announced in February that ongoing care problems have been solved.

Some telemedicine companies, including HIMS & Her, have continued to offer the composed medication. It is legal for patients to access personalized doses of the knockoffs in unique cases, e.g. HIMS & HER stated that consumers may continue to be able to access personalized cans via their website if they are clinically applicable.

In June, Hims & Hershares fell after a short-lived collaboration with more than 30% Novo Nordisk fell apart. The drugmaker said that Hims & Hins “could not adhere to the law that prohibits the creation of increased drugs” under the “wrong shape” of personalization.

For the second quarter, HIMS & HOR reported an adjusted EBITDA of $ 82 million, compared to $ 39.3 million in the previous year and the 73 million US dollar expected by Street Account.

Hims & Hin will align his quarterly call with investors at 5:00 p.m. (ET).

Do not miss these findings from CNBC Pro

Stock Diagram -iconstock -Igram -Symbol

YTD diagram by Hims & Huls Health.

– Annika Kim Constantino from CNBC contributed to this report.

On Thursday, CVS Health reported profits and income in the second quarter that exceeded estimates and increased their adjusted profit prospects, as it increased strength in its retail business and an improvement in the insurance unit in its retail pharmacy business.

The shares of the retail Drugsree chain rose by more than 1%on Thursday.

The company now expects that the adjusted profit from $ 6.40 per share is from $ 6.30 per share per share to $ 6.20 per share. CVS also lowered its GAAP yield guidelines without disclosing any additional details.

In an interview, CVS CEO David Joyner said that the quarterly beat and the instructions were partially “a homage to the work and the efforts within Aetna”, the company's insurer. He referred to a “multi -year restoration effort” at Aetna, which deals with higher medical costs in privately operated Medicare plans such as the rest of the insurance industry.

Joyner added that the retail business of CVS 'retail pharmacy business “does very well” and the efforts of the company to introduce new technologies that improve pharmacy and promote efficiency. He also pointed out the company's investments and his new prescription price model, which benefited the payer and “separated the pharmacy from the package”.

However, the company's publication states that the strength of these two business units was compensated for by a decline in the segment of the healthcare system.

The results cover the third full quarter with Joyner, a long -time CVS manager, as managing director of the retail Drugsree chain. Joyner succeeded Karen Lynch in mid -October because CVS had difficulty making higher profits and improving his stock performance.

CVS reported in the second quarter compared to the expectations of Wall Street, based on a survey of LSEG analysts:

• Win each share: $ 1.81 adapted compared to USD 1.46 per share expected
• Revenue: 98.92 billion US dollars expected compared to 94.50 billion US dollars

The company achieved a net profit of USD 1.02 Billions or 80 cents per share for the second quarter. This is compared to a net result of USD 1.77 billion or $ 1.41 per share for the period of the previous year.

With the exception of certain objects, such as B. depreciation of intangible assets, restructuring costs and capital losses, the adjusted profits were 1.81 USD per share for the quarter.

CVS booked sales of 98.92 billion US dollars for the second quarter, which rose to an increase of 8.4% compared to the same period last year, since they grow in all three business segments.

As part of a more comprehensive turnaround plan, the company will pay costs of 2 billion US dollars over the next few years. Joyner announced CNBC that the company has to close a few more locations to achieve this goal.

But he said that CVS “also focuses on the right geography” and found that the company still buys shops in Northwest's Pacific because it has no big footprint there.

Insurance pressure

All three business segments of CVS defeated Wall Street sales expectations for the second quarter. However, the company's insurance unit is still under pressure.

Aetna and other insurers dealt with higher than expected medical costs last year, since more medicare benefits return to patients in hospitals who delayed them during pandemic.

The ratio of the insurance unit – a measure of the entire medical expenditure compared to the premiums raised – rose from 89.6% in the previous year to 89.9%. A lower ratio usually indicates that a company has collected more in premiums than was paid out in services, which leads to higher profitability.

The company stated that the increase due to a fee of $ 471 million was due to a so-called premium deficiency reserve, which is related to the expected losses in the year 2025. This relates to liability that an insurer may have to cover if future bonuses are not sufficient to pay expected demands and expenses.

According to estimates of StreetCcount, the ratio in the second quarter was lower than the 90.6%, the analysts expected.

More CNBC health insurance

The insurance business booked sales of 36.26 billion US dollars in the quarter, which rose to an increase of more than 11% compared to the second quarter of 2024. Analysts expected the unit to take 34.59 billion US dollars for this period.

The department for pharmacy and consumer -wellness department of CVS booked sales of 33.58 billion US dollars in the second quarter, which rose to increase more than 12% compared to the same period in the previous year. The company said that the increase was partially due to a higher volume in the pharmacy and in the front of the business, but compensated for by the pressure of the pharmacy refund.
According to StreetCcount, analysts expected sales of $ 31.98 billion for the quarter.

This unit provides regulations in more than 9,000 retail pharmacies from CVS and offers other pharmacy services such as vaccinations and diagnostic tests.

The Health Services CVS segment achieved sales of 46.45 billion US dollars in the quarter, which rose to an increase of more than 10% compared to the same quarter in the same quarter in 2024. According to StreetCcount, analysts expected sales of 43.37 billion dollars for this period.

This unit includes Caremark, one of the largest pharmaceutical beefic managers in the country. Caremark negotiates drug discounts with manufacturers on behalf of insurance plans and creates lists of medication or form that are covered by insurance and reimburses pharmacies for recipes.

Do not miss these findings from CNBC Pro

Mounjaro, which was made by Eli Lilly and Company Packaging, can be seen in this illustration photo in a pharmacy in Krakow, Poland, on April 9, 2024.

Nurphoto | Nurphoto | Getty pictures

Eli Lilly On Thursday, his blockbuster-diabetes medication-mounjaro showed in a study in the late stage, in which he led directly with the company's older diabetes treatment, the company's trulicity.

Mounjaro met the main goal of the study to show that it was no worse than treating people with type -2 diabetes and cardiovascular diseases. Eli Lilly believes that the new data is that Mounjaro is the first choice for patients with type -2 diabetes who have a heart disease or a heart disease or stroke twice as likely with heart disease or a stroke.

The results come as a trulicity, if necessary, a best-selling medication for Eli Lilly-in front of a patent in 2027, which could further increase Mounjaro's position on the diabetes market.

Mounjaro reached the main goal of the almost five-year study and reduced the risk of cardiovascular death, heart attack or stroke by 8% compared to trulicity in adults with type 2 diabetes and cardiovascular diseases. However, the results did not meet the benchmarks of some analysts because they were considered superior to trulicity.

Nevertheless, the company said that Mounjaro showed additional, “more comprehensive” advantages over the trulicity in the study, including a lower death rate of 16% of any cause and greater kidney protection. It was the longest and greatest attempt with Tirzatide, the active ingredient in Mounjaro, which included more than 13,000 people.

Some clinicians said that the results, in particular the reduced risk of cardiovascular events, are not surprising because they assumed that Mounjaro could offer cardiovascular advantages.

But the difference in the death rate for some reason between Mounjaro and Trulicity is “really very profound” and “definitely a little clinical as a clinician,” said Dr. David Broome, clinical assistant professor at the Department of Internal Medical Code, Endocrinology and Diabetes Department at the University of Michigan.

He said the data had contributed to quantifying the difference between Mounjaro and Trulicity, which will help the providers and patients to determine the best treatment in order to advance them in their joint decisions. Broome said that the prescription decisions between patients and providers will ultimately depend on several factors, such as:

Dr. Howard Weintraub, clinical director of the center to prevent cardiovascular diseases at Nyu Langone Heart, described Mounjaro as a “winner” in the study, with the only disadvantage of him having a little more side effects than trulicity. But he said that the results may no longer motivate people to found Mounjaro, and that the higher list price of the drug could prevent insurers from covering it if it is not much better than the trulicity.

Wine grayer said he expects a lot of “dig” when the complete results were presented at a European medical meeting and published in autumn in a diary assessed by experts.

Eli Lilly saw the study results as an indicator that clinicians should choose Mounjaro for the patient group.

“It strengthens the overall story. In my opinion, the question raises:” Why wouldn't you choose Mounjaro? “,” Said Ken Custer, President of the Lilly Cardiometabolic Health.

The results “take doubts about why this is the right medication for a patient with type -2 -diabetes and type -2 -2 diabetes with cardiovascular risk,” he said, adding that it “makes it even more difficult to cover this drug for patients”.

The results also come when Eli Lilly solidified his lead Novo Nordisk On the booming market for weight loss and diabetes medication. Studies of both companies have shown the additional health benefits of their medicines for diseases such as obstructive sleep apnea and chronic kidney diseases.

Eli Lilly plans to submit the heart health data to the global supervisory authorities by the end of the year, and the company said this could lead to permits – and as part of the insurance company – by Mounjaro for this purpose in 2026. All approvals do not apply to Eli Lilly's weight loss drug -zepbound, the same active ingredient as Mooonjar, which deals with patients with darkness and not with insulation and non -denting.

The company is currently investigating the cardiovascular advantages of Zepbound in patients with obesity and specified cardiovascular diseases. According to Eli Lilly's website, the attempt by phase three is expected to be completed in 2027.

Even if the regulatory authorities agree with Mounjaro for the treatment of heart diseases in patients with type -2 -diabetes, this may not significantly expand the use of the drug. This is because the current admission of Mounjaro for Type -2 -Diabetes already covers many of these patients: According to the Heart Foundation, around 30% of people with type -2 diabetes also have a cardiovascular disease.

In a research note in June before the data, the TD Cowen -Analyst Steve Scala said that he believed that the inclusion of Tireptide would “be largely untouched” if this has similar health from the heart of trulicity.

Tirepatide “already gains” considerable acceptance “on the market due to its” strong profile “, said the analyst of Leerink Partners, David Risinger, in a separate hint in June. He said that the experts agreed that the results” would not change the decisions of doctors “regardless of whether the cardiovascular advantages of Tirzepatide were superior in the study Study.

Mounjaro showed a greater improvements than the trulicity than it was about some cardiovascular measures and the reduction in body weight and A1C, which is a measure of blood sugar levels.

The safety data of Mounjaro and Trulicity generally agreed with the past that was observed in the past. The most frequently reported unwanted events for both medicines were gastrointestinal and generally slightly to moderate heaviness.

– Angelica Peebles from CNBC contributed to this report.

The Moderna logo can be seen on April 9, 2025 in Warsaw, Poland.

Jakub Porzycki | Nurphoto | Getty pictures

Modern On Friday, the upper end of his sales outlook from 2025 lowered due to a delay in the vaccine shipping to Great Britain, but exceeded the expectations of Wall Street for the second quarter because it lowers the costs.

Moderna's shares fell by more than 9%on Friday.

The biotech company now expects the turnover of the year to be between $ 1.5 billion and $ 2.2 billion, which is due to a decrease of $ 300 million at the top of this area. The results come in one day after Moderna announced plans to reduce 10% of its workforce, which has been reinforced to a number of cost cuts, while the company deals with the Covid vaccine with falling sales and tries to bring more products onto the market.

In an interview, the CFO of Moderna, Jamey Mock, said that Spring Covid Booster to Great Britain to Great Britain at the end of this year

“It is only about deliveries from our financial year to the financial year, which happens to be the first quarter of next year to meet the offer for the Spring Booster in Great Britain,” said Mock.

Also on Friday, the company stated that less than analysts were expected in the second quarter, and achieved sales that exceeded estimates.

Moderna reported in the second quarter compared to what Wall Street had expected, based on a survey of LSEG analysts:

• Loss per share: USD 2.13 compared to an expected loss of $ 2.97
• Revenue: Expected 142 million US dollars compared to 113 million US dollars

Moderna achieved sales of $ 142 million in the second quarter, which decreased to 41% in the same period last year, since sales with the turnover of covid vaccines used. The vast majority of sales in the second quarter came from the Covid shot, which corresponded to 114 million US dollars for the period.

This exceeded the 89 million US dollars, which analysts awaited Street Account for the period, according to estimates.

However, the company said that its vaccine against the Syncytial virus of respiratory tract “negligible” sales compared to the estimates of StreetCCOUNT had the analysts compared to USD 5.9 million.

The company recorded a net loss of $ 825 million or $ 2.13 per share for the second quarter. This is compared to a net loss of $ 1.3 billion or $ 3.33 per share, which was reported for the period of previous year's section.

Mock said Moderna's efforts to reduce costs helped the company to defeat estimates for the quarter. He said that the company's operating costs in the second quarter of $ 1.6 billion dropped by $ 27% to $ 1.1 billion in the same period last year.

“If it can really read from a first half [of 2025] From a financial point of view, it is on the cost side, ”said Mock.

Do not miss these findings from CNBC Pro

US President Donald Trump, Secretary of the US Health and Human Services (HHS), Robert F. Kennedy, Jr., Dr. Mehmet OZ, administrator for the centers for Medicare & Medicaid services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (Doge). 2025.

Evelyn Hockstein | Reuters

President Donald Trump said on Thursday that he asked great pharmaceutical companies to take measures within the next 60 days to reduce the US medicinal products prices.

On Thursday in the truth social, Trump published individual letters that he sent 17 drugmakers: AbbviePresent AmgenPresent AstrazenecaBoehringer Ingelheim, Bristol Myers SquibbPresent Eli LillyEmd Serono, Genentech, GileadPresent GSKPresent Johnson & JohnsonPresent MerchantPresent NovartisPresent Novo NordiskPresent PfizerPresent RegeneroneAnd Sanofi.

Trump threatened to “use every tool in our arsenal to protect American families from further abusive drug pricing practices” when companies refuse to maintain. He asked for every company around September 29 to commit to its various goals.

The letters to Trump in May signed an executive regulation that revives a controversial plan that is known as the “most preferred nation” policy, which aims to reduce the drug costs by connecting the prices of some medicinal products to the significantly lower abroad. It was Trump's latest efforts to contain the US prescription medication prices that are on average two to three times higher than that in other industrialized nations – and up to 10 times more than in certain countries, according to the Rand Corp., a thought factory for public order.

In the letters on Thursday, Trump said that drugmakers had proposed potential solutions for high US medicinal products prices. But he said that these suggestions “promised more: postponement of the guilt and inquiries from changes in the guidelines that would lead to billions of dollars of handouts for the industry”.

He said he would only take on commitments from drug manufacturers who deliver “American families immediately relief from the strongly inflated drug prices and an end to the free trip of the American innovation by European and other developed nations”. Trump said that a joint effort to reduce the US drug prices is the “most effective way” for companies that the government and patients were.

The shares of the drug makers fell after the announcement on Thursday. Bristol Myers Squibb and Novo Nordisk's shares fell by almost 5%, the shares of GSK and Merck fell by more than 3%and the shares of Sanofi fell by more than 8%.

Here are the steps that Trump asks to take companies:

• He asked the drug manufacturers to provide their complete portfolio of existing medication at the lowest price for other industrialized ores what he describes the most suitable price as a award winner-for each individual Medicaid patient.
• Trump also asked companies to contract with the United States to guarantee that Medicare, Medicaid and Commercial payers will receive the most -shaped nation prices for all new medication at the start and in the future.
• He asked companies to negotiate toughter with what he called “foreign freeloading nations”, and added that US trade policy would try to support these efforts. He said
• He asked the drug manufacturers to adopt models that sell their medication directly to consumers or companies, which is effectively eliminated and ensure that all Americans receive the most suitable prices for nation that companies offer third parties.

A spokesman for Phrma, the largest lobby group in the industry, did not immediately answer a request for comments.

The announcement is made just a few days after Astrazeneca announced that certain drugs in the USA propose for price reductions, and that the Trump administration is considering these suggestions. Astrazeneca added that it was considering selling some medication directly to patients, which is a step that companies like Eli Lilly, Novo Nordisk, Pfizer and Bristol Myers Squibb have difficulties in the United States to afford medication

The drug manufacturers also prepare for the planned tariffs of the President for pharmaceuticals imported in the USA

The office building of the international biopharmaceutical company Astrazeneca.

CFOTO | Future publication | Getty pictures

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

President Donald Trump has put pharmaceutical companies under pressure to reduce the US drug costs, and it can possibly work – at least Astrazeneca.

Astrazeneca proposed certain drugs in the USA, his CEO Pascal Soriot told reporters on Tuesday after the company's sales and profits had taken over the estimates in the second quarter.

“We have made suggestions for what we, as a company, believe that it could be done, which actually balanced the pricing with a reduction in the United States,” said Soriot and at the same time found that the price dynamics in the country is “very complicated” and has no transparency.

He said the Trump administration checked the company's proposals, but did not indicate which treatments it contained. Astrazeneca seems to be one of the first drug makers that revealed that the Trump administration has recorded the price reductions.

“I believe that a new compensation for pricing around the world is necessary. The United States can no longer pay for the research and development of the world,” said Pascal.

“We definitely support the idea of exploiting with some reduction in the price level in the USA, and some increase, we are not talking about massive increases in Europe,” he continued.

The company has previously set itself the goal of generating sales of $ 80 billion by the end of the decade, with 50% of them or around 40 billion US dollars from the United States

Why now?

Sorio's comments come two months after Trump signed a comprehensive execution regulations that aimed at renewing a plan to reduce the US medicinal products by prices in other industrialized countries. Trump described the efforts – referred to as “most preferred nation” policy – as “compensation prices”.

We can also not forget the planned tariffs of the President for pharmaceuticals imported in the USA what could happen every day and have the consequences for pharmaceutical manufacturers and patients. The taxes aim to increase the production of domestic medications, even after Astrazeneca and other companies have announced new US investments in billions of dollars in the past few months.

Astrazeneca announced last week that it should invest $ 50 billion in strengthening its US manufacturing and research skills by 2030, including new locations and expansion of previous investments.

Soriot also said on Tuesday that he expects all of Astrazeneca to be produced on site for US patients within a few months.

He added that the company is considering selling some medication directly to patients – a step that companies such as Eli Lilly, Novo Nordisk, Pfizer and Bristol Myers Squibb have difficulty affecting medication

“We want to behave as a US company in the USA,” said Soriot.

But he added that the Astrazeneca, based in Great Britain, was “committed” to his home country, which is in the middle of reports that the company is considering moving its list in the States.

Pascal refused to comment on the rumors about the company's profit call in the second quarter.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: Doximity occurs competitive AI writing market with a new free offer

Last week, Doximity announced a new tool called doximity scribe, a free documentation solution for artificial intelligence, with which clinicians are supposed to help the time they spend on paperwork.

The company is the youngest, which immerse yourself in the heavily competitive AI writing market and has taken on the healthcare managers according to opportunities to reduce employees and discouraging administrative workload.

As with other tools on the market, Doximity Skribe AI uses to design clinical notes in real time, while the doctors determine their visits with the patient's permission. By offering the tool free of charge, Doximity follows a different approach than its competitors such as Microsoft, and others.

“Comparable writing services can cost hundreds of dollars per user and month,” said Doximity in a publication. “We believe that powerful tools like this should be accessible to all clinicians, not just for those with the budgets.”

Doximity is a digital platform for medical specialists that helps clinicians to stay up to date in medical news, find paperwork, to find transfers and to carry out telemedical appointments with patients. The company mainly achieves income through its hiring solutions and marketing for customers such as pharmaceutical companies.

In addition to doximity scribe, the company offers clinicians a AI tool called DOXIMITY GPT as well as a video and telemedicine platform called doximity dialer. In other words, this game book follows before.

But while the free offer will probably attract many clinicians, it may not yet be in the head.

Several other players in the room, including Microsoft and move away, can support deep integrations with providers from Electronic Health Record, while Doximity Skrib begins with a beta integration with its own product, the dialer. Similarly, Doximity users can choose between structured templates or freeform notes, but other providers offer support for the specialty of a provider as well as additional functions for coding and billing.

As a result, large, complex health systems will still be willing to pay AI script scholars at least for the time being.

Doximity said it would have an impact on its writer in the coming months, and clinicians can register for early access.

Read the complete announcement here.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.